PHASE I/II TRIAL OF BEVACIZUMAB, ERLOTINIB, IMATINIB

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 贝伐单抗、厄洛替尼和伊马替尼的组合将被发现比单独使用贝伐单抗和埃洛替尼显著改善治疗反应。 确定贝伐单抗、厄洛替尼和伊马替尼联合使用时的可耐受剂量水平。 评估这3种药物联合治疗晚期透明细胞肾癌的疗效。这项试验的主要终点将是客观应答率。次要终点将包括无进展存活期和总存活率。 以确定这种3种药物联合治疗晚期肾癌的总体耐受性和毒性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The combination of bevacizumab, erlotinib and imatinib will be found to substantially improve the response to treatment over bevacizumab and erlotinib alone. " To define tolerable dose levels of bevacizumab, erlotinib, and imatinib when used in combination. " To evaluate the efficacy of this 3-drug combination in the treatment of patients with advanced clear cell renal carcinoma. The primary endpoint in this trial will be the objective response rate. Secondary endpoints will include progression-free survival and overall survival. " To define the overall tolerability and toxicity of this 3-drug combination in advanced renal cell carcinoma.